Varón joven con apatía y retraimiento social progresivo

  1. Álvarez Mon, M.Á 1
  2. Alberdi Páramo, I. 2
  3. Molina Ruiz, R. 3
  1. 1 Servicio de Psiquiatría y Salud Mental, Hospital Universitario Infanta Leonor, Madrid, España
  2. 2 Departamento de Medicina y Especialidades Médicas, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, España
  3. 3 Instituto de Psiquiatría y Salud Mental, Hospital Clínico San Carlos, Madrid, España
Zugehörigkeit anzeigen +
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2023

Titel der Ausgabe: Enfermedades psiquiátricas (III)

Serie: 13

Nummer: 86

Seiten: 5114-5115

Art: Artikel

DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Bibliographische Referenzen

  • Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385-92.
  • McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al; CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-10.
  • Tungaraza TE, Farooq S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol. 2015;5(2):88-96.
  • Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry. 2014;14:102.
  • Rabinowitz J, Levine SZ, Garibaldi G, Bugarski-Kirola D, Berardo CG, Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res. 2012;137(1-3):147-50.
  • Tabarés Seisdedos R, Balanzá Martínez V, Sánchez Moreno J, Martinez Arán A, Salazar Fraile J, Selva Vera G. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord. 2008;109(3):286-99.
  • Szöke A, Trandafir A, Dupont ME, Méary A, Schürhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry. 2008;192(4):248-57.
Fuente de los datos: Dialnet